Souhaitez-vous accéder aux communiqués récents ?

Marco Taglietti, MD is appointed CEO of NanoNewron, a company developing TNF-α inhibitors for Alzheimer’s, engineered to cross the Blood-Brain Barrier

Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The "Drug Delivery Across Blood Brain Barrier Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics Market by Disease, by Drug Class, by Distribution Channel, and by Region" report has been added to ...

Dublin, Dec. 13, 2024 (GLOBE NEWSWIRE) -- The "Blood Brain Barrier Technologies Market 2024" report has been added to ResearchAndMarkets.com's offering.The blood brain barrier technologies market...

 SAN CARLOS, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Qinotto, Inc., a central nervous system (CNS) focused biopharmaceutical company that is discovering novel vehicles to deliver large molecule...

Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "Krabbe Disease Treatment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Krabbe...

Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "Blood Brain Barrier Market, 3rd Edition - Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Route of Administration,...

NeOnc’s second concurrent Phase 2 clinical study seeks further safety and preliminary evidence of biological effects of its lead drug candidate, NEO100™, on certain cancers of the brain and central...

Dublin, July 30, 2024 (GLOBE NEWSWIRE) -- The "Lewy Body Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Lewy Body Disease - Pipeline...

NEO212™ completes initial two cohorts of Phase 1 study under FDA Investigative New Drug (IND).Study tests the safety of NeOnc’s patented novel drug, NEO212™, which is the bioconjugation of its leading...